{"contentid": 488316, "importid": NaN, "name": "Tollys appoints head of clinical development", "introduction": "French biotech Tollys today announced the appointment of Dr Amina Zina\u00c3\u00af as head of clinical development.", "content": "<p>French biotech Tollys today announced the appointment of Dr Amina Zina&iuml; as head of clinical development. Dr Nasser Azli will remain in the role of chief medical officer.<br /> &nbsp;<br /> &ldquo;We are delighted to welcome Amina to our medical team,&rdquo; said Vincent Charlon, chief executive of Tollys. &ldquo;Thanks to her expertise in clinical development and in drug candidate evaluation, she will be a real asset in Tollys&rsquo; crucial next steps as we prepare to launch initial clinical trials in 2022,&rdquo; he noted.</p>\n<p>The company is developing TL-532, the first synthetic specific agonist of Toll-like receptor 3 (TLR3) cancer immunotherapy.</p>\n<p><br /> &ldquo;The drug candidate developed by Tollys has huge potential in immuno-oncology. I am keen to work with the company&rsquo;s medical team for the start of Phase I trials of TL-532, in cooperation with Nasser Azli, Tollys&rsquo; chief medical officer,&rdquo; said Dr Zina&iuml;.<br /> &nbsp;<br /> With more than 35 years&rsquo; experience in clinical development, medical affairs and drug evaluation, Dr Zina&iuml; has amassed a wealth of expertise in hematology and rare diseases while working for various biotechnology companies. Her most recent achievements include her time as project director at Servier, a French pharmaceutical group, where she implemented the strategy for the development of first-in-class allogeneic CAR-T cells in the treatment of hematological malignancies.</p>", "date": "2021-04-12 13:40:00", "meta_title": NaN, "meta_keywords": "Tollys, Appointment, Head, Clinical development, Dr Amina Zinai, TL-532", "meta_description": "Tollys appoints head of clinical development", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": "Tollys appoints head of clinical development", "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-12 13:40:10", "updated": "2021-04-12 13:47:23", "access": NaN, "url": "https://www.thepharmaletter.com/article/tollys-appoints-head-of-clinical-development", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "tollys_big.png", "image2id": "tollys_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Hematology, Immuno-oncology", "topic_tag": "Boardroom, Management, One to Watch Companies", "geography_tag": "France", "company_tag": "Tollys", "drug_tag": "TL-532", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-12 13:40:00"}